Ganglioside GD1b (porcine brain) (diammonium) is a glycosphingolipid.

G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria.

FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC50 of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC50 values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH).

FPL 66564 is a short-acting angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5.7 nM against rabbit ACE. FPL 66564 inhibits ACE activity at the functional level and is hydrolyzed in human blood into inactive hydrophilic metabolites. FPL 66564 modulates angiotensin I-induced pressor responses in anesthetized rats, and its effects rapidly return to baseline after cessation of intravenous infusion. FPL 66564 can be used for research on cardiovascular regulation related to critical illness.

Formylphosphonic acid is a nucleoside metabolite.

Fonsartan (HR720) is an AT1 receptor antagonist. Fonsartan can be used for the study of myocardial infarction (MI).

Fmoc-NH-C2-diphosphate-dexamethasone (Compound 17) is a derivative of Dexamethasone and can be used as a drug intermediate for the synthesis of the Raltitrexed-Dexamethasone conjugate.

Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC).

FLT3-IN-40 (compound 1) is a type I ATP-competitive FLT3 inhibitor with an IC50 of 16.26 nM. FLT3-IN-40 reduces the autophosphorylation level of FLT3 and the phosphorylation level of downstream ERK. FLT3-IN-40 exhibits antiproliferative, cell cycle regulatory and apoptosis-inducing activities. FLT3-IN-40 can be used in research related to acute myeloid leukemia.

Florifenine is a selective cyclooxygenase (COX) inhibitor with anti-inflammatory activity. Florifenine inhibits TXB2 in human whole blood with an IC50 of 32.5 nM. Florifenine exhibits anti-inflammatory effects in ear oedema. Florifenine inhibits neutrophil migration and reduces PGE2 levles in the inflamed ears. Florifenine inhibits leukocyte migration and PGE2 levels in the air pouch inflammation induced by Zymosan. Florifenine can be used for anti-inflammatory research.

FK 633 (FR-144633) is a fibrinogen inhibitor and peptide mimetic GPⅡbⅡa receptor antagonist. FK 633 has anti-platelet and anti-thrombotic effects. FK 633 inhibits ADP-, collagen-, thrombin-, and PAF-induced platelet aggregation with IC50 values of 103, 87, 98, and 239 nM, respectively.

FGFR4-IN-24 is a selective irreversible covalent FGFR4 inhibitor (IC50 = 1.2 nM). FGFR4-IN-24 shows much weaker activity against the other three FGFR family kinases (FGFR1-3). FGFR4-IN-24 inhibits the FGF19/FGFR4 signaling pathway, effectively suppressing the proliferation of the HuH-7 HCC cell line (GI50 = 17 nM). FGFR4-IN-24 exhibits significant antitumor activity in a HuH-7 mouse xenograft model. FGFR4-IN-24 can be used for the research of hepatocellular carcinoma.

Ferroptosis inducer-15 is a ferroptosis inducer. Ferroptosis inducer-15 downregulates GPX4 expression, triggers lipid peroxidation via ROS accumulation, and disrupts mitochondrial membrane potential to drive ferroptosis. Ferroptosis inducer-15 increases splenic CD4+ T cell proportion, promotes CD8+ cytotoxic T cell tumor infiltration, and activates antitumor immune responses. Ferroptosis inducer-15 exerts antiproliferative activity against colorectal cancer cells and inhibits tumor growth in xenograft mice models without significant body weight loss. Ferroptosis inducer-15 can be used for the research of cancer, such as colorectal cancer.

Fenaperone (hydrochloride) is a biochemical compound with neuroleptic activities.

FD2024 is a pan-PIM kinase inhibitor with IC50 values of 0.17 nM, 1.86 nM, and 0.38 nM against PIM-1, PIM-2, and PIM-3, respectively. FD2024 induces cell apoptosis. FD2024 inhibits the phosphorylation of mTOR, p70S6K, S6, 4EBP1, and BAD proteins. FD2024 exhibits anti-acute myeloid leukemia activity. FD2024 can be used in studies related to acute myeloid leukemia.

FBIN-11 (Compound 9k) is an anticancer agent. FBIN-11 induces Apoptosis mainly by increasing ROS. FBIN-11 decreases MMP. FBIN-11 exhibits anticancer effects against non-small cell lung cancer, liver cancer, and triple-negative breast cancer.

FAK-IN-29 is a selective FAK inhibitor with an IC50 of 0.5 nM. FAK-IN-29 can inhibit the proliferation and colony formation of MDA-MB-231 cells, and induce cell cycle arrest and apoptosis. FAK-IN-29 exhibits antitumor activity and can be used for the research of tumors such as triple-negative breast cancer.

Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).

Eucatropine hydrochloride is a potent muscarinic acetylcholine receptor (mAChR) inhibitor with an IC50 value of 0.583 μM. Eucatropine hydrochloride acts as an anticholinergic agent. Eucatropine hydrochloride produces behavioral effects via central cholinergic receptive sites in cats.

Erythromycin F is one of the components of Erythromycin, in which Erythromycin is a cyclic lactone antibiotic.

Ercalcidiol-13C3 (25-Hydroxy Vitamin D2-13C3) is the 13C-labeled Ercalcidiol. Ercalcidiol is a metabolite of vitamin D2, is regarded as an indicator of vitamin D nutritional status.

EP4 receptor antagonist 8 is an orally active EP4 antagonist (human EP4 IC50 = 6.40 nM). EP4 receptor antagonist 8 significantly reduced paw and joint swelling, inflammatory cell infiltration, cartilage damage, pannus formation, and joint bone erosion in arthritis (AIA) mice in a dose-dependent manner. EP4 receptor antagonist 8 can be used for the study of inflammatory pain.

Enciprazine dihydrochloride is an orally active non-benzodiazepine anxiolytic. Enciprazine dihydrochloride acts as an agonist of 5-HT1A receptor (5-HT1AR) and an antagonist of α1-adrenergic receptor (α1-adrenergic receptor) . Enciprazine dihydrochloride induces drug-related electroencephalogram changes by reducing the average power of δ waves and θ waves, and increasing the average power of α waves and fast β waves. Enciprazine dihydrochloride exhibits anti-aggressive activity, with only weak sedative and ataxic effects. Enciprazine dihydrochloride regulates plasma corticosterone levels and activates the hypothalamic-pituitary-adrenal axis. Enciprazine dihydrochloride can be used in research related to anxiety disorders, generalized anxiety syndrome and psychosis.

EML631 is a SPIN1 inhibitor with a Kd of 3-7 μM. EML631 interacts with the second Tudor domain of SPIN1 and blocks its ability to read the H3K4me3 histone mark. EML631 inhibits the coactivator activity of SPIN1 in the Wnt signaling pathway and reduces the activity of Wnt response reporter genes. EML631 can be used in cancer-related research.

Elpetrigine (JZP 4) is a potent calcium and sodium channel blocker. Elpetrigine has anticonvulsant, antidepressant, antimania and anxiolytic effects. Elpetrigine can be used in the research of epilepsy and bipolar disorder.

EGIS-7625 free base is an orally active and selective competitive antagonist of 5-HT2B receptor, with a human Ki value of 1 nM. EGIS-7625 free base shows low affinity for 5-HT2A and 5-HT2C receptors. The pKi values of EGIS-7625 free base for human 5-HT2B, 5-HT2A and 5-HT2C are 9.0, 6.2 and 7.7, respectively. EGIS-7625 free base alleviates mCPP-induced hypoactivity.

EGFR-IN-208 is an allosteric mutant EGFRL858R/T790M and EGFRL858R/T790M/C797S inhibitor, with IC50 values of 3.06 μM and 1.08 μM, respectively. EGFR-IN-208 binds to the allosteric site of EGFR and inhibits EGFR phosphorylation. EGFR-IN-208 induces apoptosis and exhibits antiproliferative effects in cancer cells. EGFR-IN-208 can be used in research related to non-small cell lung cancer.

EGFR-IN-203 is a EGFR kinase domain inhibitor targeting EGFRT790M/C797S/V948R. EGFR-IN-203 stably binds to the allosteric pocket of EGFR in an inactive conformation. EGFR-IN-203 can be used in research related to cancers such as non-small cell lung cancer.

EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer.

EGFR-IN-193 is an EGFR inhibitor, which can be used to synthesize PROTACs as target protein ligands, such as PROTAC EGFR degrader 17.